Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a recent company event.
President and CEO Richard Paulson and Chief Medical Officer Reshma Rangwala discussed the company’s late-breaker ASCO presentation for SENTRY, a Phase 3 study evaluating selinexor plus ruxolitinib in newly diagnosed myelofibrosis patients with baseline platelet counts above 100. Rangwala said the ASCO presentation will be the first public medical-congress presentation of the data and is expected to cover clinical endpoints, safety and disease-modification measures.
